Eumentis Therapeutics, Inc. — Form D
Eumentis Therapeutics, Inc. of NEWTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2024-06-26. The offering totals $2.0M, of which $765K was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2024-06-26
- Form: D
- Accession: 0001823359-24-000002
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $2.0M
- Amount sold: $765K
- Remaining: $1.2M
- Minimum investment: $20K
- Investors: 11
- Date of first sale: 2021-08-16
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-516970
Issuer
- Name: Eumentis Therapeutics, Inc.
- CIK: 0001823359
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2019
- Address: 508 DUDLEY ROAD, NEWTON, MA, 02459
- Phone: 6174133020
Officers, directors & promoters (8)
| Name | Role | Location |
|---|
| Maryann Bryla | Director | Newton, MA |
| James Larrick | Director | Osage Beach, MO |
| Kim Patrick | Director | Newton, MA |
| Andrew Pearlman | Director | Newton, MA |
| Mark Tepper | Director | Newton, MA |
| Randall Marshall | Executive Officer | Newton, MA |
| Mark Tepper | Executive Officer | Newton, MA |
| Amar Kapur | Director | Newton, MA |
Other filings by this issuer (3)
More